Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Retatrutide should not be used during pregnancy or breastfeeding, as no human safety data exist for these situations
Undereating can lead to reduced exercise performance and increased risk of muscle wasting
Understanding the Bone Turnover Data One of the most important findings from the Hansen trial is the pattern of bone turnover markers
Do KQ, Trabesinger AH, Kirsten-Krger M, Lauer CJ, Dydak U, Hell D, et al
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unlicensed by the MHRA or EMA and still being evaluated in Phase 2 and Phase 3 clinical trials
US$ 29.91
US$ 27.44
US$ 22.31
US$ 20.35
US$ 22.53
US$ 20.47
